Evidence map›Paper›PMID 30913862›Full record

ArticleCancer research and treatment2019

Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer.

Maria Sfakianaki, Chara Papadaki, Maria Tzardi, Maria Trypaki, Sardar Alam, Eleni D Lagoudaki, Ippokratis Messaritakis, Odysseas Zoras, Dimitris Mavroudis, Vassilis Georgoulias and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pan-Cancer Computational Analysis of RKIP (International journal of molecular sciences · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Prognostic Value ofCancers · 2022
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Maria SfakianakiLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
Chara PapadakiLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
Maria TzardiDepartment of Pathology, University General Hospital of Heraklion, Iraklio, Greece.
Maria TrypakiLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
Sardar AlamLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
Eleni D LagoudakiLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
Ippokratis MessaritakisLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
Odysseas ZorasDepartment of Surgical Oncology, University General Hospital of Heraklion, Iraklio, Greece.
Dimitris MavroudisLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
Vassilis GeorgouliasSchool of Medicine, University of Crete, Heraklion, Greece.
John SouglakosLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
University of Crete · GRUniversity Hospital of Heraklion · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to investigate the prognostic significance of liver kinase b1 (LKB1) loss in patients with operable colon cancer (CC). MATERIALS AND

methodsTwo hundred sixty-two specimens from consecutive patients with stage III or high-risk stage II CC, who underwent surgical resection with curative intent and received adjuvant chemotherapy with fluoropyrimidine and oxaliplatin, were analyzed for LKB1 protein expression loss, by immunohistochemistry as well as for KRAS exon 2 and BRAFV600E mutations by Sanger sequencing and TS, ERCC1, MYC, and NEDD9 mRNA expression by real-time quantitative reverse transcription polymerase chain reaction.

resultsLKB1 expression loss was observed in 117 patients (44.7%) patients and correlated with right-sided located primaries (p=0.032), and pericolic lymph nodes involvement (p=0.003), BRAFV600E mutations (p=0.024), and TS mRNA expression (p=0.041). Patients with LKB1 expression loss experienced significantly lower disease-free survival (DFS) (hazard ratio [HR], 1.287; 95% confidence interval [CI], 1.093 to 1.654; p=0.021) and overall survival (OS) (HR, 1.541; 95% CI, 1.197 to 1.932; p=0.002), compared to patients with LKB1 expressing expressing tumors. Multivariate analysis revealed LKB1 expression loss as independent prognostic factor for both decreased DFS (HR, 1.217; 95% CI, 1.074 to 1.812; p=0.034) and decreased OS (HR, 1.467; 95% CI, 1.226 to 2.122; p=0.019).

conclusionLoss of tumoral LKB1 protein expression, constitutes an adverse prognostic factor in patients with operable CC.

Indexed as

Down-RegulationAdaptor Proteins, Signal TransducingAdultAgedAMP-Activated Protein Kinase KinasesChemotherapy, AdjuvantColonic NeoplasmsDNA-Binding ProteinsEndonucleasesFemaleHumansMaleMiddle AgedMutationNeoplasm StagingOxaliplatinAdaptor Proteins, Signal TransducingAMP-Activated Protein Kinase KinasesBRAF protein, humanDNA-Binding ProteinsEndonucleasesERCC1 protein, humanKRAS protein, humanMYC protein, humanNEDD9 protein, humanOxaliplatinProtein Serine-Threonine KinasesProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)PyrimidinesSTK11 protein, humanBRAFLKB1MSIPrognosisStage II-IIIΚRAS

Identifiers

PMID30913862
PMCPMC6790836
OpenAlexW2925053146

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.